Business Context and Reporting Period
This Form 8-K is a current report filed by MedaSorb Technologies Corporation (referred to in metadata as Cytosorbents Corp) for the reporting period ending December 31, 2008. The filing, dated January 7, 2009, addresses significant changes in the company's executive leadership and board composition effective as of December 31, 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The filing reports the following departures and appointments effective December 31, 2008:
- Al Kraus: Resigned as President and Chief Executive Officer. He remains a member of the Board of Directors. The resignation was not due to any disagreement with the Company.
- Dr. Phillip Chan, M.D., Ph.D.: Appointed as Interim Chief Executive Officer. He is a current Board Director with medical training from Harvard and Yale. No material compensation agreement was finalized at the time of filing, though one is expected shortly.
- Dr. James Winchester: Resigned as Chief Medical Officer. His departure was not due to any disagreement. The Company is in discussions to replace him, but no definitive agreement has been entered into.
- Mr. William Miller: Stepped down as Chairman of the Board of Directors. His departure was not due to any disagreement. The Company is in discussions to replace him, but no definitive agreement has been entered into.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or specific risk factors. The primary contingency noted is the ongoing search for permanent replacements for the Chief Medical Officer and the Chairman of the Board, with no definitive agreements in place as of the filing date.
Investor Verification Checklist
- Verify the finalization of the compensation agreement for Interim CEO Dr. Phillip Chan.
- Confirm the identity and appointment status of the new Chief Medical Officer.
- Confirm the identity and appointment status of the new Chairman of the Board.
- Review subsequent filings for any financial data or strategic shifts resulting from the leadership transition.